Technivie (Ombitasvir / Paritaprevir / Ritonavir)

In Europe, Technivie is sold under the trade name Viekirax. Both brands are made by AbbVie.

Prescription Technivie contains the combination of ombitasvir, paritaprevir and ritonavir. Technivie is an antiviral medicine for the treatment of chronic hepatitis C. Technivie prevents the hepatitis virus from multiplying and infecting cells in your body, clearing your blood of the virus over time.
Paritaprevir and ombitasvir are protein blockers while ritonavir is classified as a booster as it prevents the breakdown of the active drug paritaprevir in the body.

Technivie is taken with other medicines such as Exviera (dasabuvir) and Copegus (ribavirin) as per your physicians instructions. Technivie interacts with many medicines so be sure to discuss all medicines, vitamins and herbs you are taking with your physician.

While you are taking Technivie, your doctor will be testing your blood to determine how well you are responding to the treatment.

The standard adult dose of Technivie is 2 tablets at one time in the morning with food. Swallow the tablets whole with water, do not crush, chew or break the tablets of Technivie. Children are not to be given Technivie. Do not stop taking Technivie unless your physician tells you, even if you feel well. You will have the best results if you continue taking Technivie for the duration prescribed. Do not miss a dose of Technivie, but if you do miss a dose and it is not more than 12 hours late, take as soon as you remember, if longer than 12 hours, skip that dose and continue the next day. Do not take double your regular dose of Technivie.

In 2019, when comparing Technivie to USA Technivie coupon price, InsulinHub was found to offer a discount of approximately 20% in Technivie savings. 

Buy Technivie from InsulinHub.com for the best Technivie cost.

Information about Technivie (Ombitasvir / Paritaprevir / Ritonavir)

Technivie is a combination medication that includes ombitasvir, paritaprevir, and ritonavir. It is used to treat chronic hepatitis C virus (HCV) infection in adults, specifically for genotype 4 HCV. The medication works by inhibiting different stages of the HCV life cycle, which helps prevent the virus from replicating. Ombitasvir and paritaprevir are direct-acting antivirals (DAAs), while ritonavir acts as a pharmacokinetic enhancer, helping to increase the effectiveness of paritaprevir by inhibiting its metabolism.

Product Highlights

• Technivie is primarily indicated for treating chronic HCV infection in adult patients with genotype 4 hepatitis C without cirrhosis.
• It may also be used in patients co-infected with HIV, but only when HIV is well-controlled with other medications.

Key Ingredient

• Ombitasvir
• Paritaprevir
• Ritonavir

Key Benefits

• Technivie has been shown to provide high rates of sustained virologic response (SVR), meaning the virus is undetectable after treatment.
• The once-daily regimen simplifies treatment adherence, improving patient convenience compared to multiple-dose regimens.
• It provides an effective treatment option for genotype 4 hepatitis C, a strain that is more challenging to treat with other medications.
• By controlling HCV replication, Technivie helps reduce the risk of liver damage and complications, including cirrhosis and liver cancer.

Direction of Use

• The recommended dose is one tablet (ombitasvir 12.5 mg, paritaprevir 75 mg, ritonavir 50 mg) taken once daily with food.
• Take the tablet at the same time every day, ideally with a meal to help absorption and reduce gastrointestinal side effects.
• If a dose is missed, take it as soon as possible, unless it is nearly time for the next dose. In this case, skip the missed dose and continue with the regular schedule. Do not take two doses at once.

Safety Concerns

• Ritonavir is known to interact with many medications because it inhibits liver enzymes that metabolize other drugs. Careful management of other medications, especially those metabolized by CYP3A, is essential.
• As with all HCV treatments, liver function should be monitored regularly. Technivie should be used cautiously in patients with pre-existing liver conditions.
• Some individuals may experience allergic reactions to one of the ingredients, such as rash, itching, or swelling. Immediate medical attention should be sought if signs of a serious allergic reaction occur.
• Technivie is not recommended during pregnancy due to the potential risk to the fetus. It is also not known if the medication passes into breast milk, so caution is advised in breastfeeding.
• If treatment is stopped prematurely or if it’s not used correctly, there may be an increased risk of developing drug-resistant strains of HCV.

Avoid Technivie (Ombitasvir / Paritaprevir / Ritonavir) If

• Technivie should be avoided in patients with moderate or severe liver impairment (Child-Pugh B or C).
• Patients who are allergic to any ingredient in Technivie (ombitasvir, paritaprevir, or ritonavir) should not take this medication.
• Technivie is contraindicated with certain medications, such as rifampin, ergot derivatives, and st. john’s wort, as they can interfere with its effectiveness or increase the risk of severe side effects.
• Technivie is not recommended for use during pregnancy due to potential harm to the fetus. Women of childbearing potential should use reliable contraception throughout the treatment. 
• Due to unknown risks, it is not recommended for use while breastfeeding unless deemed necessary by a healthcare provider.